The persistent infection of the gastric mucosa by Helicobacter pylori (H. pylori) and the resulting chronic inflammation are a risk factor for gastric carcinogenesis.
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality worldwide. It is estimated that 75% of deaths occur in developing countries.
The Helicobacter pylori type IV secretion system (T4SS) encoded by the cag pathogenicity island forms needle-like pili, whose binding to the integrin-β1 receptor results in injection of the CagA oncoprotein.
Helicobacter pylori is the most important pathogen associated with gastric diseases, including gastric cancer. Cytotoxin-associated gene A (CagA) is an oncoprotein and a major virulence factor of H. pylori.
Helicobacter pylori is an infectious agent associated with gastrointestinal diseases. There are several reports about the use of probiotics strains with antimicrobial activity, as treatment to eradicate H. pylori.
The Helicobacter pylori infection is the main cause of diseases benign and maligns gastrointestinal. Although, the cure clinical rate has reduced for an increase of antimicrobial resistance in worldwide. For this reason, the search of alternatives that might optimize the effectiveness is a need.